Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 214

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 214
---
 glucose levels, with secretion of adequate amounts of insulin in direct response to glucose levels. Thus, IsletRx
has the potential to functionally replace patients’ malfunctioning Islet cells by secreting physiological levels of insulin to maintain
long-term continuous balanced glucose. IsletRx, as allogeneic islet cells for diabetic patients derived from an unlimited source of pluripotent
stem cells, can overcome the shortage in adequate biological material for islet transplantation therapy.

Conventional treatments (Insulin syringes and
pumps) are designed to monitor blood glucose levels in diabetics externally, and to inject insulin artificially according to the amount
needed (insulin is given directly into the blood by injections or by the pumps). This treatment has several disadvantages, including:
dependence on injections and external monitoring of blood glucose levels; the necessity to operate, maintain and fill the pumps, which
affects the patients’ quality of life; artificial injection of insulin, which does not prevent the deterioration of diabetes over
time; and excessive insulin injection, which may cause the glucose level to drop and lead to fainting, loss of consciousness and even
death in extreme situations. On the contrary, IsletRx has the potential to functionally replace patients’ malfunctioning Islet cells
by secreting the exact physiological levels of insulin to maintain long-term continuous balanced glucose levels with minimal risk, personal
comfort and increased compliance for treatment.

Strengths

Kadimastem’s vision is to utilize cell therapy
treatments for incurable diseases that impair patients’ life expectancy and quality of life, such as Type 1 diabetes. The strategy
is to replace the functionality of malfunctioning cells even within some distance from the original tissue/organ that is difficult or
impossible to replace. The activity of malfunctioning insulin secreting cells can be restored using “healthy” islet cells
that perform their physiological role upon their implantation.

Kadimastem believes they have the potential to
transform the lives of individuals living with Type 1 Diabetes and in the future Type 2 Diabetes which are insulin dependent.

Kadimastem’s key competitive strengths include:

  Kadimastem developed large scale manufacturing capabilities  

  Kadimastem plans to utilize multiple delivery strategies,  

  Kadimastem has a unique, IP protected technology for “enrichment”                                                             

IsletRx - Development of a
Drug for the Treatment of Diabetes

The IsletRx cells for diabetes therapy Kadimastem
develop